---
title: "HER2-targeted antibody–molecular glue conjugate drives selective cyclin K degradation"
id: "biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.12.760175v1?rss=1"
published_at: "2026-11-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# HER2-targeted antibody–molecular glue conjugate drives selective cyclin K degradation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.12.760175v1?rss=1)
- **Published At:** 2026-11-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study presents a strategy to redirect a potent small-molecule **molecular glue** degrader toward antigen-positive cells by conjugating it to an antibody specific for **HER2**. - Investigators designed SAS1001, a CCNK (cyclin K) molecular glue with a solvent-exposed piperazine to enable linker attachment without loss of activity. - SAS1001 induced ubiquitin–proteasome system-dependent depletion of **cyclin K** and reduced proliferation across multiple breast cancer cell lines. - Conjugation of SAS1001 to **trastuzumab** produced the antibody–degrader conjugate Tz-SS2009, which preferentially internalized in **HER2**-positive cells and enhanced CCNK degradation in those cells. - The trastuzumab conjugate showed greater antiproliferative effects in HER2-positive versus HER2-negative cells and outperformed an isotype-matched non-targeting conjugate. - Whole-proteome analysis confirmed selective **cyclin K** loss and downstream transcriptional changes consistent with disruption of the **CDK12/CCNK** complex. - Authors reported that, within the CR8/DS18 purine scaffold series, substitution at a solvent-exposed position retained CCNK degradation when displayed on a full-length IgG. - The study extends antibody-directed degradation beyond CRBN-based glues by identifying a linker attachment point on a glue scaffold that preserves biochemical activity when presented on an antibody. - The source did not report in vivo efficacy data, clinical dosing, safety profiles, or detailed pharmacokinetics; investigators noted the intrinsic challenge that broad expression and essential functions of the CDK12/CCNK complex may constrain the therapeutic window of highly potent glues. - Authors declared no competing interests and listed multiple public funders supporting the work.
## Clinical Analysis & Structured Key Points
A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation | bioRxiv Skip to main content New Results A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation View ORCID Profile Sofia Srdanovic , View ORCID Profile Alina Chrzastek , View ORCID Profile Laura C. Helbling , View ORCID Profile Pauline Franz , Aidan B Pidd , View ORCID Profile Damjan Lalović , View ORCID Profile Lea N.C. Rochet , Amy McIntosh , View ORCID Profile Janine Gray , View ORCID Profile Jack W Houghton , Jianan Lu , View ORCID Profile Josephine Walton , Thomas Mills , View ORCID Profile Vanessa Stöcker , View ORCID Profile Nicolas Veillard , Paul W. Hogg , View ORCID Profile Zuzanna Kozicka , View ORCID Profile Edward W. Tate doi: https://doi.org/10.64898/2026.11.12.760175 Sofia Srdanovic 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sofia Srdanovic Alina Chrzastek 2 ADC Therapeutics; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Alina Chrzastek Laura C. Helbling 3 EPFL Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Laura C. Helbling Pauline Franz 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Pauline Franz Aidan B Pidd 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Damjan Lalović 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Damjan Lalović Lea N.C. Rochet 2 ADC Therapeutics; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lea N.C. Rochet Amy McIntosh 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Janine Gray 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Janine Gray Jack W Houghton 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jack W Houghton Jianan Lu 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Josephine Walton 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Josephine Walton Thomas Mills 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vanessa Stöcker 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Vanessa Stöcker Nicolas Veillard 2 ADC Therapeutics; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nicolas Veillard Paul W. Hogg 2 ADC Therapeutics; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Zuzanna Kozicka 3 EPFL Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Zuzanna Kozicka Edward W. Tate 1 Imperial College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Edward W. Tate For correspondence: e.tate{at}imperial.ac.uk Abstract Info/History Metrics Supplementary material Preview PDF Abstract Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and pharmacological degradation of CCNK has emerged as a promising strategy for disrupting CDK12-dependent transcriptional programs. However, the broad expression and essential functions of the CDK12/CCNK complex may limit the therapeutic window of highly potent molecular glue degraders. Here, we investigate whether antibody-mediated delivery can impart cellular selectivity to a molecular glue degrader through targeting the HER2 receptor. Molecular glues lack the modular architecture of PROTACs, thus linker placement can be the central design problem. We designed SAS1001, a CCNK molecular glue degrader with a solvent-exposed piperazine primed for linker attachment. SAS1001 induced potent and ubiquitin-proteasome system-dependent degradation of CCNK and inhibited proliferation in a range of breast cancer cells. Conjugation to trastuzumab (Tz) generated the HER2-targeted degrader-antibody conjugate Tz-SS2009, which internalized preferentially in HER2-positive cells and produced enhanced CCNK degradation and antiproliferative effects, relative both to HER2-negative cells and to an isotype-matched non-targeting conjugate. Whole proteome analysis further demonstrated CCNK depletion and revealed downstream changes consistent with established roles of the CDK12/CCNK complex in transcriptional regulation. These findings demonstrate that antibody-mediated delivery can redistribute the cellular activity of a potent molecular glue degrader towards antigen-positive cells. In the CR8/DS18 purine series, substitution at a solvent-exposed position preserved CCNK degradation when the degrader was delivered on a full-length IgG. More broadly, this work extends antibody-directed degradation beyond the CRBN-based glues that have dominated the field and illustrates how structural characterization of a glue scaffold can identify a linker attachment point that does not compromise activity. Competing Interest Statement The authors have declared no competing interest. Funder Information Declared Engineering and Physical Sciences Research Council , 2753945 , 2753246 , 2741582 Swiss National Science Foundation , P500-2_235357 European Commission , 101282234 Cancer Research UK , DRCNPG-Nov21\100001 , SEBPCTA-2024/100003 Medical Research Council , MR/X502959/1 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 13, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation Sofia Srdanovic , Alina Chrzastek , Laura C. Helbling , Pauline Franz , Aidan B Pidd , Damjan Lalović , Lea N.C. Rochet , Amy McIntosh , Janine Gray , Jack W Houghton , Jianan Lu , Josephine Walton , Thomas Mills , Vanessa Stöcker , Nicolas Veillard , Paul W. Hogg , Zuzanna Kozicka , Edward W. Tate bioRxiv 2026.11.12.760175; doi: https://doi.org/10.64898/2026.11.12.760175 Share This Article: Copy Citation Tools A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation Sofia Srdanovic , Alina Chrzastek , Laura C. Helbling , Pauline Franz , Aidan B Pidd , Damjan Lalović , Lea N.C. Rochet , Amy McIntosh , Janine Gray , Jack W Houghton , Jianan Lu , Josephine Walton , Thomas Mills , Vanessa Stöcker , Nicolas Veillard , Paul W. Hogg , Zuzanna Kozicka , Edward W. Tate bioRxiv 2026.11.12.760175; doi: https://doi.org/10.64898/2026.11.12.760175 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8164) Biochemistry (19027) Bioengineering (15171) Bioinformatics (45975) Biophysics (22958) Cancer Biology (20299) Cell Biology (27562) Clinical Trials (138) Developmental Biology (14274) Ecology (21588) Epidemiology (2067) Evolutionary Biology (25993) Genetics (16461) Genomics (24046) Immunology (19234) Microbiology (43597) Molecular Biology (18537) Neuroscience (96102) Paleontology (718) Pathology (3074) Pharmacology and Toxicology (5265) Physiology (8362) Plant Biology (16431) Scientific Communication and Education (2124) Synthetic Biology (4688) Systems Biology (10473) Zoology (2440)
## Related Clinical Research

- [Phase-space Geometry of NF-κB Networks Modulates Phenotypic Plasticity in Breast Cancer](https://medichelpline.com/clinical-feed/pubmed-43037823.md) (DOI: 10.1007/s11538-026-01797-y)
- [ERBB2 Activating Mutations Increase Trastuzumab Deruxtecan Activity in HER2-Nonamplified mBC](https://medichelpline.com/clinical-feed/pubmed-42714867.md) (DOI: 10.1158/1078-0432.CCR-26-0198)
- [Normalized membrane ratio of TROP2 predicts response to datopotamab deruxtecan in NSCLC](https://medichelpline.com/clinical-feed/nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with.md)
- [5-year iDFS After PET-Guided Chemotherapy De-escalation in HER2-Positive Early Breast Cancer (PHER](https://medichelpline.com/clinical-feed/nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast.md)
- [EHR-driven Analysis of Sequential ADC Orders in Breast Cancer Using Human-Guided Agentic AI](https://medichelpline.com/clinical-feed/medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.